ProState blood test detects with very high accuracy prostate cancer patients who can be managed by Active Surveillance.
ProState lab test is highly accurate, detecting with almost 100% certainty, 50% of patients who can be safely be monitored.
ProState prevents overtreatment of prostate cancer patients by radical prostatectomy surgery or radiotherapy.
Prostate cancer patients can enjoy good quality of life without side-effects of unnecessary aggressive therapy.
Correct assignment of prostate cancer patients to active surveillance lowers cost burden to patient and healthcare system. (Filson 2017).
CE Mark of the prostate cancer blood test is expected by Q1-2020.
For collaborative research and partnering enquiries write to firstname.lastname@example.org.